Veracyte, Inc. - Common Stock (NQ:VCYT)

45.81 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗

September 16, 2024

A Relative Strength Rating upgrade for Tempus AI shows improving technical performance.

Via Investor's Business Daily

Topics Artificial Intelligence

New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

September 15, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

September 04, 2024

From Veracyte, Inc.

Via Business Wire

A Glimpse Into The Expert Outlook On Veracyte Through 4 Analysts ↗

May 08, 2024

Via Benzinga

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 26, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

August 26, 2024

From Veracyte, Inc.

Via Business Wire

Thermo Fisher Scientific Stock Sees RS Rating Jump To 81 ↗

August 13, 2024

Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81.

Via Investor's Business Daily

Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio? ↗

August 11, 2024

Lumen, Upstart, ADMA, Sweetgreen, Veracyte, Clear Secure, and Core Scientific were best performers last week. Did you invest in them?

Via Benzinga

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View ↗

August 07, 2024

Veracyte reports Q2 sales of $114.43M, a 27% increase year over year, surpassing the $100.3 million consensus. Testing revenue rose 31% to $107 million, driven by strong performance of Decipher...

Via Benzinga

Shopify Posts Upbeat Earnings, Joins Axon Enterprise, Aspen Technology, Illumina, Global Payments And Other Big Stocks Moving Higher On Wednesday ↗

August 07, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

August 07, 2024

Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!

Via InvestorPlace

VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Veracyte Announces Second Quarter 2024 Financial Results

August 06, 2024

From Veracyte, Inc.

Via Business Wire

The 3 Best Personalized Nutrition Stocks to Buy Now ↗

July 24, 2024

Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions.

Via InvestorPlace

Topics Artificial Intelligence

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

July 17, 2024

From Veracyte, Inc.

Via Business Wire

Trading SMID Biotech Stocks In A Volatile Market ↗

July 01, 2024

Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a...

Via Talk Markets

Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness ↗

June 10, 2024

On Monday, Cathie Wood-led Ark Invest made a significant move by reducing its holdings in Robinhood Markets Inc (NASDAQ:HOOD). This decision came amidst a period of market fluctuations and followed a...

Via Benzinga

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

June 03, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

May 22, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in Upcoming Investor Conferences

May 15, 2024

From Veracyte, Inc.

Via Business Wire

VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024 ↗

May 07, 2024

VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Veracyte Announces First Quarter 2024 Financial Results

May 07, 2024

From Veracyte, Inc.

Via Business Wire

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

May 06, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

April 22, 2024

From Veracyte, Inc.

Via Business Wire

New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

April 22, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

April 16, 2024

From Veracyte, Inc.

Via Business Wire

Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally ↗

February 28, 2024

On Wednesday, Cathie Wood-led Ark Invest made a significant move by selling over $17 million worth of Coinbase Global Inc (NASDAQ:COIN) shares.

Via Benzinga

Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold ↗

February 27, 2024

On Tuesday, Cathie Wood-led Ark Invest adjusted its portfolio, making significant trades.

Via Benzinga

Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

February 27, 2024

From Veracyte, Inc.

Via Business Wire

Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed ↗

February 26, 2024

On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such as Robinhood Markets Inc (NASDAQ:HOOD) and Coinbase Global Inc (NASDAQ:

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.